+1 877 302 8632
+1 888 205 9894 (Toll-free)

Recombinant SARS-CoV-2 Spike S1 antibody (RBD)

Reactivity: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Beta, SARS CoV-2 Eta, SARS CoV-2 Kappa, SARS CoV-2 Omicron, SARS CoV-2 Delta ELISA, IF, Crys, SPR, mIHC Host: Human Monoclonal CR3022 unconjugated Recombinant Antibody
Catalog No. ABIN6952546
Plus shipping costs $50.00
200 μg
Shipping to: United States
Delivery in 7 to 11 Business Days
  • Key Features
    • Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
    • Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta), B.1.1.529 (omicron), B.1.429 (epsilon), B.1.525 (eta), and B.1.617.1 (kappa).
    • Frequently used as reference in S-protein ELISAs and neutralization assays.
    • Synergizes with other hNAbs: binds a highly conserved epitope, not interefering with the S-protein's ACE2 RBD.
    Target See all SARS-CoV-2 Spike S1 Antibodies
    SARS-CoV-2 Spike S1
    Antibody Type
    Recombinant Antibody
    Binding Specificity
    • 19
    • 2
    • 2
    • 2
    • 1
    SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Beta, SARS CoV-2 Eta, SARS CoV-2 Kappa, SARS CoV-2 Omicron, SARS CoV-2 Delta
    • 15
    • 11
    • 6
    • 6
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    • 38
    • 7
    • 5
    • 38
    • 4
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This SARS-CoV-2 Spike S1 antibody is un-conjugated
    • 43
    • 14
    • 10
    • 8
    • 8
    • 6
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    ELISA, Immunofluorescence (IF), Crystallization (Crys), Surface Plasmon Resonance (SPR), Multiplex Immunohistochemistry (mIHC)
    Recombinant monoclonal antibody CR3022 to SARS-CoV S Glycoprotein.

    The antibody CR3022 binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

    While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).

    Cross-Reactivity (Details)
    The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Protein A affinity purified
    The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
    IgG1 kappa
  • Application Notes
    This antibody (CR3022) binds to both SARS-CoV and SARS-CoV-2 with high affinity. The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1 is available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).
    For Research Use only
  • Validation #104441 (Multiplex Immunohistochemistry)
    'Independent Validation' Badge
    Akoya Biosciences
    SARS-CoV-2 Spike S1
    Lot Number
    Method validated
    Multiplex Immunohistochemistry
    Positive Control

    FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2

    Negative Control

    SARS-CoV-2-negative placenta patient sample


    Passed. The anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 produced staining in FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2.

    'Independent Validation' Badge
    Validation Images
    Full Methods
    Primary Antibody
    Secondary Antibody
    Full Protocol
    • Protocol details are described in the Akoya Biosciences CODEX® User Manual (see
    • Tissue preparation as outlined in the Akoya Biosciences CODEX® User Manual FFPE tissue protocol.
    • Conjugation of the anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 as described in Chapter 4 of the Akoya Biosciences CODEX® User Manual.
    • Autofluorescence quenching according to the Autofluorescence Quenching Protocol for CODEX® (see
    Experimental Notes
  • Format
    1 mg/mL
    PBS with 0.02 % Proclin 300.
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Kannenberg, Trawinski, Henschler, Buhmann, Hönemann, Jassoy: "Antibody course and memory B-cell response in the first year after SARS-CoV-2 infection." in: The Journal of infectious diseases, (2022) (PubMed).

    Jacobsen, Fabricius, Class, Topfstedt, Lorenzetti, Janowska, Schmidt, Staniek, Zernickel, Stamminger, Dietz, Zellmer, Hecht, Rauch, Blum, Ludwig, Jahrsdörfer, Schrezenmeier, Heeg, Mayer, Seidel, Groß et al.: "High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection. ..." in: Nature communications, Vol. 13, Issue 1, pp. 7315, (2022) (PubMed).

    Hennrich, Sawatsky, Santos-Mandujano, Banda, Oberhuber, Schopf, Pfaffinger, Wittwer, Riedel, Pfaller, Conzelmann: "Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization." in: PLoS pathogens, Vol. 17, Issue 4, pp. e1009064, (2021) (PubMed).

    Tian, Li, Huang, Xia, Lu, Shi, Lu, Jiang, Yang, Wu, Ying: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody." in: Emerging microbes & infections, Vol. 9, Issue 1, pp. 382-385, (2020) (PubMed).

    Stadlbauer, Amanat, Chromikova, Jiang, Strohmeier, Arunkumar, Tan, Bhavsar, Capuano, Kirkpatrick, Meade, Brito, Teo, McMahon, Simon, Krammer: "SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup." in: Current protocols in microbiology, Vol. 57, Issue 1, pp. e100, (2020) (PubMed).

    Yuan, Wu, Zhu, Lee, So, Lv, Mok, Wilson: "A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV." in: Science (New York, N.Y.), (2020) (PubMed).

    Pinto, Park, Beltramello, Walls, Tortorici, Bianchi, Jaconi, Culap, Zatta, De Marco, Peter, Guarino, Spreafico, Cameroni, Case, Chen, Havenar-Daughton, Snell, Telenti, Virgin, Lanzavecchia, Diamond et al.: "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody." in: Nature, (2020) (PubMed).

    ter Meulen, van den Brink, Poon, Marissen, Leung, Cox, Cheung, Bakker, Bogaards, van Deventer, Preiser, Doerr, Chow, de Kruif, Peiris, Goudsmit: "Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants." in: PLoS medicine, Vol. 3, Issue 7, pp. e237, (2007) (PubMed).

  • Target
    SARS-CoV-2 Spike S1
    SARS-CoV-2 Spike S1 Products
    E2 antibody, Surface Glycoprotein antibody, S antibody
    Target Type
    Viral Protein
    Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV
You are here: